Literature DB >> 2766619

Prostaglandin-induced hyperostosis. A case report.

D M Drvaric1, W J Parks, J B Wyly, K J Dooley, W H Plauth, E W Schmitt.   

Abstract

The use of prostaglandin-E1 (PGE1) to maintain patency of the ductus arteriosus in infants with ductal-dependent congenital heart disease is now well established. A 2.5-month-old child with cyanotic heart disease who required long-term PGE1 infusions; developed widespread periosteal reactions during the course of therapy. Prostaglandin-induced subperiosteal hyperostosis should now be considered in the differential diagnosis of neonatal cortical proliferation.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2766619

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.176


  4 in total

1.  Plain film and CT observations in prostaglandin-induced bone changes.

Authors:  M A Matzinger; V A Briggs; H J Dunlap; K Udjus; D J Martin; P McDonald
Journal:  Pediatr Radiol       Date:  1992

2.  A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders.

Authors:  Robert C Gensure; Outi Mäkitie; Catherine Barclay; Catherine Chan; Steven R Depalma; Murat Bastepe; Hilal Abuzahra; Richard Couper; Stefan Mundlos; David Sillence; Leena Ala Kokko; Jonathan G Seidman; William G Cole; Harald Jüppner
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 3.  Lesions of juxtacortical origin (surface lesions of bone).

Authors:  S Kenan; I F Abdelwahab; M J Klein; G Hermann; M M Lewis
Journal:  Skeletal Radiol       Date:  1993       Impact factor: 2.199

4.  Regulation of prostaglandin EP1 and EP4 receptor signaling by carrier-mediated ligand reuptake.

Authors:  Yuling Chi; Sylvia O Suadicani; Victor L Schuster
Journal:  Pharmacol Res Perspect       Date:  2014-07-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.